http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-031495-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_311fa17c942cd6d665866a1119290e8a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
| filingDate | 2016-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fe1755ead2d4b8ce2e1d0422b003bc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_472cac2bc40c16c89ebe58bcbe9bc6b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f70bc45d3a9e39a63cfcfeb0a32a9567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d81e4fae55324350f6b0cf127ff4bc36 |
| publicationDate | 2019-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-031495-B1 |
| titleOfInvention | ANTITUBERCULAR VACCINE ON THE BASIS OF RECOMBINANT PROTEINS Ag85B, TB10.4, FliC |
| abstract | The invention relates to molecular biology, biotechnology, medicine. A tuberculosis vaccine containing recombinant proteins Ag85B and TB10.4 M. tuberculosis, as well as recombinant adjuvant - flagellin FliC Salmonella enterica serovar Typhimurium, as well as a pharmaceutically acceptable excipient, is proposed for solving the acute problem of modernity, which is to create a safe environment, to create a safe, erudite excipient in order to solve a modern problem, to create a safe, erudite excipient, to create a safe, erudite excipient, to create a safe, modern, non-toxic excipient to solve an acute problem of modernity to create a safe, erudite excipient to deal with an effective, modern excipient, to create a safe, erudite excipient, to create a safe, discharging, to create a safe, modern, effective excipient for solving the acute problem of modernity in creating a safe, unpredictable excipient to solve the problem of an effective sweep, which creates a safe, erectile, phytochemuline enterophilus Typhimurium. with efficacy at least comparable to that of BCG. These properties of the proposed vaccine are confirmed by examples. |
| priorityDate | 2015-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.